Article Text

PDF
Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis
  1. Stéphane Hilliquin1,2,
  2. Benjamin Hugues1,2,
  3. Stéphane Mitrovic1,2,
  4. Laure Gossec1,2,
  5. Bruno Fautrel1,2
  1. 1 Rheumatology, UPMC, Institut Pierre Louis d'épidémiologie et Santé publique, GRC 08, Paris, France
  2. 2 Department of Rhumatologie, AP-HP, GH Pitié Salpêtrière, Paris, France
  1. Correspondence to Prof Bruno Fautrel, UPMC, Institut Pierre Louis d'épidémiologie et Santé publique, GRC 08, Paris 75646, France; bruno.fautrel{at}aphp.fr

Abstract

Background Recent advances in knowledge of the pathogenesis of rheumatoid arthritis (RA) has led to promoting very early intervention.

Objectives To assess the efficacy of therapeutic interventions in preventing or delaying RA onset with a systematic literature review (SLR) and meta-analysis (MA).

Methods The SLR aimed to include all reports of randomised controlled trials of disease-modifying antirheumatic drugs or glucocorticoids used in patients presenting genetic and/or environmental risk factors for RA and/or systemic autoimmunity associated with RA, and/or symptoms without clinical arthritis and/or unclassified arthritis and in patients with RA. We searched PubMed, EMBASE and Cochrane databases for English articles published from 2006 to 2016 using the keywords ‘undifferentiated arthritis’ or ‘very early rheumatoid arthritis’ with ‘therapy’ or ‘treatment’. Main outcome was RA occurrence, defined as fulfilment of the 1987 ACR criteria. The MA was performed with RevMan with the Mantel-Haenszel method.

Results Among 595 abstracts screened, 10 reports of trials were selected. The studies included 1156 patients, with mean symptom duration 16.2±12.6 weeks. The occurrence of RA was available for nine studies, assessing methylprednisolone, methotrexate, a tumour necrosis factor blocker, abatacept or rituximab. In the group arthralgia without arthritis (people at risk of RA), the MA of the two available studies did not show significant reduction in RA occurrence at week 52 or more (pooled OR 0.74, 95% CI 0.37 to 1.49). For people with undifferentiated arthritis, the MA of the seven available studies revealed significant risk reduction with OR 0.73(95% CI 0.56 to 0.97).

Conclusions This MA demonstrates that early therapeutic intervention may significantly reduce the risk of RA onset in this very first phase of the disease.

  • rheumatoid arthritis
  • treatment
  • corticosteroids
  • dmards (synthetic)
  • dmards (biologic)

Statistics from Altmetric.com

Footnotes

  • SH and BH contributed equally.

  • Handling editor Josef S Smolen

  • Contributors BF had the initiative for drafting this article. The literature search and writing of the article were performed equally by BH and SH. The data layout, meta-analysis and rereading was carried out by SM. The overall proofreading was achieved by both BF and LG.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Ethics Committee/Institutional Review Board approval obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.